<DOC>
	<DOCNO>NCT00246974</DOCNO>
	<brief_summary>The primary objective study ass activity ZD1839 250 mg daily addition standard chemotherapy patient advance metastatic transitional cell carcinoma urothelium estimate time progression .</brief_summary>
	<brief_title>Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologicallyconfirmed transitional cell carcinoma urothelium Locally advance metastatic disease At least one measurable lesion define RECIST Chemotherapynaiv Previous chemotherapy systemic antitumour therapy Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma , cervical cancer situ locally limited prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>Transitionel cell cancer urothelium</keyword>
</DOC>